Edition:
United States

Paion AG (PA8G.DE)

PA8G.DE on Xetra

2.26EUR
18 May 2018
Change (% chg)

€0.06 (+2.96%)
Prev Close
€2.19
Open
€2.25
Day's High
€2.26
Day's Low
€2.22
Volume
9,846
Avg. Vol
67,256
52-wk High
€3.53
52-wk Low
€2.04

Chart for

About

Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In... (more)

Overall

Beta: 0.76
Market Cap(Mil.): €134.32
Shares Outstanding(Mil.): 61.12
Dividend: --
Yield (%): --

Financials

  PA8G.DE Industry Sector
P/E (TTM): -- 223.30 32.53
EPS (TTM): -0.20 -- --
ROI: -48.21 -8.07 12.63
ROE: -48.21 -10.87 14.50

BRIEF-Paion FY Net Loss At EUR 12.1 Million

* SAYS CASH AND CASH EQUIVALENTS OF EUR 24.8 MILLION AS OF 31 DECEMBER 2017

Mar 22 2018

BRIEF-PAION Grants Exclusive License To Mundipharma For Development And Commercialization Of Remimazolam In Japan

* SAID ON SUNDAY GRANTED EXCLUSIVE LICENSE TO MUNDIPHARMA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN JAPAN

Dec 18 2017

BRIEF-PAION announces clinical development progress with remimazolam

* DGAP-NEWS: PAION ANNOUNCES CLINICAL DEVELOPMENT PROGRESS WITH REMIMAZOLAM BY ITS PARTNER HANA PHARM IN SOUTH KOREA

Nov 23 2017

Earnings vs. Estimates